TORONTO - Health Canada has ordered the anti-inflammatory drug Prexige off the market, citing the potential for serious liver-related adverse events.
In a release, the department said it was stopping sales and would cancel market authorization for lumiracoxib, which is sold by Novartis Pharmaceuticals Canada Inc. as Prexige. In a statement posted on its website, the company said it will comply with Health Canada's request.